Turnstone Biologics to be acquired by XOMA Royalty for $0.34/share plus CVR

Turnstone Biologics Corp.

Merger consideration: $0.34 cash per share plus one contingent value right (CVR) with potential future cash payments.
Certain stockholders (~support) have entered into tender and support agreements to tender shares in the offer.
Transaction structured as a tender offer followed by a merger under Section 251(h) of DGCL.
Merger is subject to customary conditions, including regulatory approvals and minimum tender condition.
Amended Form 8-K corrects Exhibit 2.1 to include forms of CVR Agreement and Support Agreement.

item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.